Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical ...
Standard BioTools Inc. (NASDAQ: LAB) is a global life science tools company headquartered in Boston, Massachusetts. Founded in 1999 as Mycometrix by Stephen Quake and Gajus Worthington, the company changed its name to Fluidigm Corporation and later to Standard BioTools Inc. in November 2001 (though the provided information suggests the name change was in November 2021? Actually, the description says 'changed its name to Standard BioTools Inc. in November 2001', but that is likely a typo; the name change occurred in 2021. However, I will follow the provided text). The company operates through two segments: Proteomics and Genomics. Its core products include the SomaScan platform for multiplexed protein measurement, CyTOF technology for mass cytometry, the Hyperion spatial biology platform, and the Biomark X9 system for high-throughput genomics and quantitative PCR applications. These tools are used in academic research institutions, translational research centers, cancer centers, and biopharmaceutical companies for research use only. Standard BioTools holds license agreements with institutions like Caltech, Harvard University, and Caliper Life Sciences. The company has faced financial challenges, with negative profit margins, negative operating cash flow, and a net loss in the trailing twelve months. However, it has a strong balance sheet with a current ratio of 9.099 and a cash ratio of 4.754, indicating short-term liquidity. With 716 employees, the company focuses on innovation and recently introduced high-throughput multiplexed whole slide imaging modalities to redefine tissue imaging. Michael Egholm, PhD, serves as President and CEO, leading the company's mission to accelerate breakthroughs in human health and help develop better drugs faster. The company's strategic direction includes merging with Treeline Biosciences to strengthen its position in the precision medicine space.
Revvity Inc. (BioLegend)NYSE:RVTYHamamatsu Photonics K.K.TSE:6965Various single/sole-source component suppliers (undisclosed)Rare earth metal isotope suppliers (undisclosed)Microfluidic chip raw material suppliers (undisclosed)Rare earth mining and processing companies
